Rich Edwards
Chief Technology Officer Nuclide Therapeutics
Richard Edwards is Co-Founder and CTO of Nuclide Tx, where he leads radiochemistry, GMP manufacturing, and technical strategy for the development of next-generation radiopharmaceuticals. He has over a decade of experience in radiopharmaceutical development, with particular expertise in radiohalogen chemistry, spanning fluorine, iodine and astatine isotopes for cancer imaging and therapy. Richard completed his PhD in Radiochemistry at Cardiff University before holding research positions at the IECB, The Institute of Cancer Research, and King’s College London. His work has resulted in high-impact publications, patented technologies, successful licensing agreements, and more than £1.6 million in translational funding for theranostic programmes.
Seminars
Experience a fast-paced debate, where isotope specialists will each present the strongest case for their radionuclide before joining a moderated discussion comparing clinical evidence, manufacturing readiness, supply considerations and commercial potential. Hear contrasting perspectives, challenge conventional thinking and take part in the discussion as the audience helps determine which isotope will define the next five years of TRP development.
- Comparing the scientific, clinical, manufacturing and commercial advantages of emerging isotopes including Actinium-225, Lead-212, Copper-67, Terbium, Astatine-211 and Lutetium-177
- Evaluating which radionuclides are best positioned to win across therapeutic efficacy, supply scalability, dosimetry flexibility, theranostic integration and global clinical applicability
- Challenging each isotope expert to defend why their radionuclide will become the hottest, most commercially impactful and most clinically transformative isotope over the next five years
- Evaluating where Actinium-225 offers meaningful clinical advantages over established beta-emitting radionuclides to maximise patient benefit
- Overcoming isotope supply, manufacturing and infrastructure constraints to enable sustainable clinical development and future commercialisation
- Optimising target selection, dosimetry and therapeutic index to improve efficacy while minimising off-target toxicity
- Preparing novel radiopharmaceutical technologies for successful GMP tech transfer and clinical manufacturing
- Lessons learned navigating analytical, CMC and operational challenges during technology transfer
- Coordinating discovery, manufacturing and clinical teams to enable seamless progression into Phase I
- Key considerations for de-risking technology transfer while maintaining programme momentum
